Items where Subject is "RM Therapeutics. Pharmacology"

Library of Congress subjects (102130) R Medicine (9801) RM Therapeutics. Pharmacology (256)
Number of items at this level: 256.
2026
  • Choi, Yujin, Lee, Boram, Kim, Pyung-Wha, Park, A-La, Cho, Seung-Hun (2026). Acupuncture as adjunctive treatment for schizophrenia: a systematic review and meta-analysis. Asian Journal of Psychiatry, 117, https://doi.org/10.1016/j.ajp.2026.104844 picture_as_pdf
  • Cousin, Emma M., Martin, Kristi, Hansen, Ryan N., Coster, John, Sullivan, Sean D. (2026). Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028. Journal of Managed Care & Specialty Pharmacy, 32(1), 3 - 13. https://doi.org/10.18553/jmcp.2025.25253
  • Li, Kevin H., Cousin, Emma M., Gabriel, Nico, Sullivan, Sean D. (2026). Integrating price benchmarks and comparative clinical effectiveness to predict initial price offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027). Value in Health, 29(1), 64 - 72. https://doi.org/10.1016/j.jval.2025.09.3054
  • Magalhães, Pedro V.S., Tedeschi, Eduardo, Hoffmann, Mauricio S. (2026). Clinical response to a second course of electroconvulsive therapy: within- and between-person analysis of a retrospective cohort. Psychiatry Research, 355, https://doi.org/10.1016/j.psychres.2025.116857
  • Shahzad, Mahnum, DuBois, Steven G, Costa, Rebecca, Argetsinger, Stephanie, Ross-Degnan, Dennis, Bourgeois, Florence T, Wagner, Anita K (2026). Assessment of oral anticancer medicines in pediatric patients before the Research to Accelerate Cures and Equity (RACE) Act, 2007-2021. Journal of Pediatrics, 290, https://doi.org/10.1016/j.jpeds.2025.114949
    • 2025
  • Al-Omar, Hussain Abdulrahman, Al-Muhsin, Asma Abdulaziz, Almudaiyan, Lolwa, Hassan Al-Najjar, Amal, Abu Esba, Laila Carolina, Almodaimegh, Hind, Altawil, Esraa, Yousef, Consuela, Khan, Mansoor & AlYahya, Khalid et al (2025). HPR10 A strategic national framework for managed entry agreements to access innovative and breakthrough medications in Saudi Arabia. Value in Health, 28(12, Supplement 1), S323. https://doi.org/10.1016/j.jval.2025.09.1420
  • Al-Omar, Hussain Abdulrahman, Almuhsin, Asma Abdulaziz, Almudaiyan, Lolwa Hamad, Al-Najjar, Amal Hassan, Abu Esba, Laila Carolina, Almodaimegh, Hind, Altawil, Esraa S., Yousef, Consuela Cheriece, Khan, Mansoor Ahmed & Alyahya, Khalid et al (2025). A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop. Journal of Medical Economics, 28(1), 753 - 765. https://doi.org/10.1080/13696998.2025.2506967 picture_as_pdf
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanavos, Panos (2025). HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024). Value in Health, 28(6, Supplement 1), S254. https://doi.org/10.1016/j.jval.2025.04.1054
  • Bergsteedt, Matthew, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA92 Diffusion and launch sequencing of cell and gene therapies across the USA, Europe, Canada and Australia. Value in Health, 28(6, Supplement 1), S263 - S264. https://doi.org/10.1016/j.jval.2025.04.1103
  • Cherla, Avi, Wagner, Anita K., Wouters, Olivier J., Woloshin, Steven, Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines. JAMA, 334(16), 1480 - 1482. https://doi.org/10.1001/jama.2025.13917 picture_as_pdf
  • Civitelli, Diego, Kanavos, Panos (2025). HPR2 A case study: how England implemented its first Population Health Agreement. Value in Health, 28(12, Supplement 1), S321. https://doi.org/10.1016/j.jval.2025.09.1412
  • Civitelli, Diego, Satish, Kavyashree, Kanavos, Panos (2025). HSD8 A case-study on the implementation of the Population Health Agreement for Inclisiran in England. Value in Health, 28(6, Supplement 1), S226. https://doi.org/10.1016/j.jval.2025.04.904
  • Civitelli, Diego, Therianos, Panagiotis, Gill, Jennifer, Kanavos, Panos (2025). HTA222 Life-years lost due to regulatory and reimbursement delays: a study of oncology drugs across England, Scotland, and France, 2022-2024. Value in Health, 28(12, Supplement 1), S448. https://doi.org/10.1016/j.jval.2025.09.2006
  • Ecker, Hanne, Liang, Ava (2025). EE163 Cost-effectiveness analysis of ribociclib with endocrine therapy for treatment with premenopausal women with HR positive HER2 negative early breast cancer in the UK. Value in Health, 28(12, Supplement 1), S133. https://doi.org/10.1016/j.jval.2025.09.547
  • Ecker, Hanne, Liang, Ava (2025). EE163 Cost-effectiveness analysis of ribociclib with endocrine therapy for treatment with premenopausal women with HR positive HER2 negative early breast cancer in the UK. Value in Health, 28(12, Supplement 1), S133. https://doi.org/10.1016/j.jval.2025.09.547
  • Grueger, Jens, Martin, Kristi, Sullivan, Sean D. (2025). Referencing drug prices of other countries may not sustainably lower prices in the United States: lessons from Europe. Value in Health, 28(9), 1305 - 1308. https://doi.org/10.1016/j.jval.2025.06.010
  • Jofre-Bonet, Mireia, McGuire, Alistair, Dayer, Victoria, Roth, Joshua A, Sullivan, Sean D (2025). The price effects of biosimilars in the United States. Value in Health, 28(5), 742 - 750. https://doi.org/10.1016/j.jval.2025.02.008
  • Main, Caitlin, Schafer, Cathrin, Kanavos, Panos (2025). From vision to reality: the EU's pharmaceutical reforms and the path to improved access. PHARMACOECONOMICS-OPEN, 9(3), 331 - 339. https://doi.org/10.1007/s41669-024-00556-w picture_as_pdf
  • McGonigle, Rylee, Naci, Huseyin, Siebert, Maximilian, Ouvina, Michelle, Gutierrez-Sacristan, Alba, Wagner, Anita K., Bourgeois, Florence T. (2025). Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: a retrospective cohort study. PLoS Medicine, 22(12). https://doi.org/10.1371/journal.pmed.1004651 picture_as_pdf
  • McIntyre, Finlay, Lin, Ryan, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA155 From license to reimbursement: a slot-based ML framework for seamless MA to HTA alignment. Value in Health, 28(12, Supplement 1), S433 - S434. https://doi.org/10.1016/j.jval.2025.09.1940
  • Naci, Huseyin, Murphy, Peter, Woods, Beth, Lomas, James, Wei, Jinru, Papanicolas, Irene (2025). Population health impact of NICE-recommended new drugs – authors' reply. The Lancet, 405(10497), 2277 - 2278. https://doi.org/10.1016/S0140-6736(25)01078-5
  • Naci, Huseyin, Murphy, Peter, Woods, Beth, Lomas, James, Wei, Jinru, Papanicolas, Irene (2025). Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. The Lancet, 405(10472), 50 - 60. https://doi.org/10.1016/S0140-6736(24)02352-3 picture_as_pdf
  • Naci, Huseyin, Shahzad, Mahnum, Murphy, Peter, Zhang, Yichen, Costa, Rebecca, Ross, Joseph S., Wagner, Anita K. (2025). Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation. BMJ Medicine, 4(1). https://doi.org/10.1136/bmjmed-2025-001934 picture_as_pdf
  • Oo, Myo Myo Swe, Jayawardana, Sahan, Campbell, Allen, Aitken, Murray, Patel, Kershaw V., Nasir, Khuram, Mehra, Mandeep, Mossialos, Elias (2025). Trends in global glucose lowering medication consumption insights from pharmaceutical sales data (2010–2021). PLOS Global Public Health, 5(10). https://doi.org/10.1371/journal.pgph.0005326 picture_as_pdf
  • O’Neill, Emily T., Huang, Andrew W., Wilson-Barthes, Marta, Manji, Imran, Kigen, Gabriel, Busakhala, Naftali, Nyanje, Samuel, Galárraga, Omar, Pastakia, Sonak D. (2025). A cost-effectiveness analysis of rivaroxaban compared to warfarin for the management of venous thromboembolism in Western Kenya. Clinical Drug Investigation, 45(8), 565 - 574. https://doi.org/10.1007/s40261-025-01454-7 picture_as_pdf
  • Parkes, Isaac (2025). Evaluating a proposed psychological therapy service for addiction and severe mental health problems. Journal of Mental Health Policy and Economics, 28(Supplement 1).
  • Ramagopalan, Sreeram V, Thaker, Harshal, Walker, Mel, Narasimhan, Om (2025). How much do ex-US revenues make a difference for pharmaceutical investment returns? Journal of Comparative Effectiveness Research, 14(10). https://doi.org/10.57264/cer-2025-0121 picture_as_pdf
  • Roth, Joshua A, Dayer, Victoria W., Jofre-Bonet, Mireia, McGuire, Alistair, Sullivan, Sean D. (2025). Defining a framework for sustainable global biosimilars markets using findings from a targeted literature review. BioDrugs, 39(3), 411-425. https://doi.org/10.1007/s40259-025-00710-8
  • Schätz, L., Goulart, M., Cirillo, R., Hernandez, D., Peristeris, P., Poschenrieder, A., Papaioannou, P., Kanavos, P., la Fougère, C., Holzwarth, U. (2025). 2305P Are European healthcare systems prepared for a potential rapid rise in radioligand therapy eligible patient numbers? Annals of Oncology, 36(Supplement 2), S1267. https://doi.org/10.1016/j.annonc.2025.08.2921
  • Sullivan, Sean D., Cousin, Emma M., Li, Kevin H., Gabriel, Nico, Martin, Kristi (2025). Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation. Journal of Managed Care & Specialty Pharmacy, 31(10), 968 - 981. https://doi.org/10.18553/jmcp.2025.25199
  • Sun, Lucille, Veenstra, David L, Brufsky, Adam, Pluard, Timothy, Sandin, Rickard, Stergiopoulos, Stella, Liu, Xianchen, Williams, Troy, Sullivan, Sean D (2025). First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: a real-world cost-effectiveness assessment in a US Medicare-eligible population. Journal of Managed Care & Specialty Pharmacy, 31(10), 1039 - 1050. https://doi.org/10.18553/jmcp.2025.25063
  • Therianos, Panagiotis, Kyriopoulos, Ilias-Ioannis, Kanavos, Panos (2025). HTA82 Comparing HTA outcomes and rationale for decision making between countries with mature vs. newly founded HTA systems: evidence from England, France, and Greece. Value in Health, 28(12, Supplement 1), S417 - S418. https://doi.org/10.1016/j.jval.2025.09.1867
  • Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin, Wagner, Anita Katharina, Ross, Joseph S., Guan, Xiaodong (2025). Strength of evidence supporting cancer drug approvals in China, 2017-2021. Journal of Clinical Oncology, 43(16_suppl). https://doi.org/10.1200/jco.2025.43.16_suppl.tps11188
  • Zhang, Yichen, Li, Huangqianyu, Chen, Jinyu, Naci, Huseyin, Wagner, Anita K, Shi, Luwen, Guan, Xiaodong (2025). Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study. BMJ Evidence-Based Medicine, https://doi.org/10.1136/bmjebm-2025-113722 picture_as_pdf
    • 2024
  • Alani, A. H., Eaves, K., Mills, Mackenzie, Kanavos, P. (2024). HTA246 Improving access to innovative therapies for rare bleeding disorders: evidence from high income countries. Value in Health, 27(12), S402 - S403. https://doi.org/10.1016/j.jval.2024.10.2071
  • Boentert, Matthias, Berger, Kenneth I., Díaz-Manera, Jordi, Dimachkie, Mazen M., Hamed, Alaa, Riou França, Lionel, Thibault, Nathan, Shukla, Pragya, Ishak, Jack, Caro, J. Jaime (2024). Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease. Orphanet Journal of Rare Diseases, 19(1). https://doi.org/10.1186/s13023-023-02974-1 picture_as_pdf
  • Chavez, D., Tolkmitt, F., Mills, M., Kanavos, P. (2024). PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process. Value in Health, 27(12, Supplement), S323 - S323. https://doi.org/10.1016/j.jval.2024.10.3814
  • Civitelli, D., Politopoulou, K., Mills, Mackenzie, Kanavos, P. (2024). HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Value in Health, 27(12, Supplement), S356 - S356. https://doi.org/10.1016/j.jval.2024.10.1843
  • D'Amico, Francesco, Navarrete, Jaime, Montero-Marín, Jesús, Cardeñosa-Valera, Eugenia, Navarro-Gil, Mayte, Pérez-Aranda, Adrián, López-del-Hoyo, Yolanda, Collado-Navarro, Carlos, García-Campayo, Javier, Luciano, Juan V. (2024). Cost-utility of attachment-based compassion therapy (ABCT) and Mindfulness-Based Stress Reduction (MBSR) in the management of depressive, anxious, and adjustment disorders in mental health settings: economic evaluation alongside a randomized controlled trial. Mindfulness, 15(3), 559 - 569. https://doi.org/10.1007/s12671-024-02319-4 picture_as_pdf
  • Forlano, Roberta, Stanic, Tijana, Jayawardana, Sahan, Mullish, Benjamin H., Yee, Michael, Mossialos, Elias, Goldin, Robert D., Petta, Salvatore, Tsochatzis, Emmanouil & Thursz, Mark R. et al (2024). Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community. PLOS ONE, 19(9). https://doi.org/10.1371/journal.pone.0307500 picture_as_pdf
  • Gallego, Ana, Serrat, Mayte, Royuela-Colomer, Estíbaliz, Sanabria-Mazo, Juan P., Borràs, Xavier, Esteve, Montserrat, Grasa, Mar, Rosa, Araceli, Rozadilla-Sacanell, Antoni & Almirall, Miriam et al (2024). Study protocol for a three-arm randomized controlled trial investigating the effectiveness, cost-utility, and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia. Digital Health, 10, https://doi.org/10.1177/20552076241239177 picture_as_pdf
  • Harnisch, Michelle, Barnett, Michael l., Coussens, Stephen, Thomas, Kali s., Olfson, Mark, Berhane, Kiros, Sacarny, Adam (2024). Physician antipsychotic overprescribing letters and cognitive, behavioral, and physical health outcomes among people with dementia: a secondary analysis of a randomized clinical trial. JAMA network open, 7(4). https://doi.org/10.1001/jamanetworkopen.2024.7604 picture_as_pdf
  • Hernandez, Inmaculada, Sullivan, Sean D. (2024). Net prices of new antiobesity medications. Obesity, 32(3), 472 - 475. https://doi.org/10.1002/oby.23973
  • Hernandez, Inmaculada, Cousin, Emma M., Wouters, Olivier J., Gabriel, Nico, Cameron, Teresa, Sullivan, Sean D. (2024). Price benchmarks of drugs selected for medicare price negotiation and their therapeutic alternatives. Journal of Managed Care & Specialty Pharmacy, 30(8), 762 - 772. https://doi.org/10.18553/jmcp.2024.24153 picture_as_pdf
  • Hill, Andrew, Tovar sanchez, Tamara, Delaporte, Eric, Sokhela, Simiso, Simmons, Bryony, Kouanfack, Charles, Mccann, Kaitlyn, Levi, Jacob, Fairhead, Cassandra, Venter, Francois (2024). Low CD4 counts predict excessive weight gains during first-line treatment for HIV. Journal of Antimicrobial Chemotherapy, 79(9), 2369 - 2378. https://doi.org/10.1093/jac/dkae238 picture_as_pdf
  • Jayawardana, Sahan, Campbell, Allen, Aitken, Murray, Andersson, Charlotte E., Mehra, Mandeep R., Mossialos, Elias (2024). Global consumption patterns of combination hypertension medication: an analysis of pharmaceutical sales data from 2010–2021. PLOS Global Public Health, 4(9). https://doi.org/10.1371/journal.pgph.0003698 picture_as_pdf
  • Jenei, Kristina, Gentilini, Arianna, Haslam, Alyson, Prasad, Vinay (2024). Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. The Lancet Oncology, 25(8), 979 - 988. https://doi.org/10.1016/S1470-2045(24)00286-9 picture_as_pdf
  • Jones, Arun M., Serra-Sastre, Victoria, Kim, Hansoo (2024). The impact of generic entry of pharmaceuticals in Australia. Value in Health Regional Issues, 43, https://doi.org/10.1016/j.vhri.2024.101008 picture_as_pdf
  • Lee, Donghoon, Kim, SangJune, Dugan, Jerome A. (2024). The effect of prescription drug insurance on the incidence of potentially inappropriate prescribing: evidence from Medicare Part D. Health Economics (United Kingdom), 33(1), 137 - 152. https://doi.org/10.1002/hec.4766 picture_as_pdf
  • Leon, Giovanny, Gonzalez-Pier, Eduardo, Kanavos, Panos, Ruiz de Castilla, Eva Maria, Machinicki, Gerardo (2024). The 30-billion-dollar distribution markups and taxes of pharmaceuticals in Latin American countries: impact, options, and trade-offs. Value in Health Regional Issues, 44, https://doi.org/10.1016/j.vhri.2024.101015 picture_as_pdf
  • Li, Yutong, Cardoso-Silva, Jonathan, Kelly, John M., Delves, Michael J., Furnham, Nicholas, Papageorgiou, Lazaros G., Tsoka, Sophia (2024). Optimisation-based modelling for explainable lead discovery in malaria. Artificial Intelligence in Medicine, 147, https://doi.org/10.1016/j.artmed.2023.102700 picture_as_pdf
  • Martineau, Samuel, Cristea, Ioana-Alina, Chevance, Astrid, Fanelli, Daniele, Naudet, Florian (2024). Are large prospective trials on antidepressants in mental disorders seeding trials?: a descriptive study of trials registered on ClinicalTrials.gov. BMJ Open, 13(8), e062913. https://doi.org/10.1136/bmjopen-2022-062913 picture_as_pdf
  • Michaeli, D. T., Michaeli, J. C., Mossialos, E., Albers, S., Michaeli, C. T. (2024). 640P Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials. Annals of Oncology, 35(Supplement 2), S508 - S508. https://doi.org/10.1016/j.annonc.2024.08.707
  • Namale, Phiona E., Boloko, Linda, Vermeulen, Marcia, Haigh, Kate A., Bagula, Fortuna, Maseko, Alexis, Sossen, Bianca, Lee-Jones, Scott, Msomi, Yoliswa & McIlleron, Helen et al (2024). Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial. Trials, 25(1). https://doi.org/10.1186/s13063-024-08119-4 picture_as_pdf
  • Nomikos, N., Naoum, P., Athanasakis, K., Kyriopoulos, I (2024). Cost-effectiveness analysis of filgotinib versus tofacitinib as first-line treatments for rheumatoid arthritis in Greece. Value in Health, 27(12, Supplement), S80 - S80. https://doi.org/10.1016/j.jval.2024.10.418
  • Nomikos, N., Naoum, P., Athanasakis, K., Kyriopoulos, I (2024). EE477 A budget impact analysis of introducing filgotinib for the treatment of rheumatoid arthritis in Greece. Value in Health, 27(12 Supplement), S149. https://doi.org/10.1016/j.jval.2024.10.758
  • Nomikos, N., Naoum, P., Athanasakis, K., Kyriopoulos, I (2024). EE478 A budget impact analysis of introducing filgotinib as a first-line treatment for moderate to severe ulcerative colitis in Greece. Value in Health, 27(12 Supplement), S149. https://doi.org/10.1016/j.jval.2024.10.759
  • Nomikos, N., Naoum, P., Athanasakis, Kostas, Kyriopoulos, I (2024). Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece. Value in Health, 27(12, Supplement), S80 - S80. https://doi.org/10.1016/j.jval.2024.10.419
  • Osipenko, Leeza (2024). Does industry really develop less medicine with clinical benefit?—Reply. JAMA Internal Medicine, 184(5), p. 587. https://doi.org/10.1001/jamainternmed.2024.0180
  • Salcher-Konrad, Maximilian, Nguyen, Mary, Savović, Jelena, Higgins, Julian P. T., Naci, Huseyin (2024). Treatment effects in randomized and nonrandomized studies of pharmacological interventions: a meta-analysis. JAMA network open, 7(9). https://doi.org/10.1001/jamanetworkopen.2024.36230 picture_as_pdf
  • Sanabria-Mazo, Juan P., D'Amico, Francesco, Cardeñosa, Eugenia, Ferrer-Forés, Monserrat, Edo, Sílvia, Borràs, Xavier, McCracken, Lance M., Feliu-Soler, Albert, Sanz, Antoni, Luciano, Juan V. (2024). Economic evaluation of videoconference group Acceptance and Commitment Therapy and Behavioral Activation Therapy for depression versus usual care among adults with chronic low back pain plus comorbid depressive symptoms. Journal of Pain, 25(7). https://doi.org/10.1016/j.jpain.2024.01.337 picture_as_pdf
  • Shahzad, Mahnum, Naci, Huseyin, Esselen, Katharine M., Dottino, Joseph A., Wagner, Anita K. (2024). Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. Journal of Pharmaceutical Policy and Practice, 17(1). https://doi.org/10.1080/20523211.2024.2351003 picture_as_pdf
  • Sullivan, Sean D., Chaturvedi, Shruti, Gautam, Preety, Arnaud, Alix (2024). Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States. Journal of Managed Care & Specialty Pharmacy, 31(1). https://doi.org/10.18553/jmcp.2025.24271
  • Tedeschi, Eduardo, Hoffmann, Mauricio S., Magalhães, Pedro V.S. (2024). Moderating effects of diagnosis and gender on the influence of age on electroconvulsive therapy outcome. Acta neuropsychiatrica, 36(3), 185 - 186. https://doi.org/10.1017/neu.2024.4 picture_as_pdf
  • Thorlund, Kristian, Duffield, Stephen, Popat, Sanjay, Ramagopalan, Sreeram, Gupta, Alind, Hsu, Grace, Arora, Paul, Subbiah, Vivek (2024). Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of Comparative Effectiveness Research, 13(3). https://doi.org/10.57264/cer-2023-0147 picture_as_pdf
  • Tinelli, Michela, Roddy, Áine, Knapp, Martin, Arango, Celso, Mendez, Maria Andreina, Cusak, James, Murphy, Declan, Canitano, Roberto, Oakley, Bethany, Quoidbach, Vinciane (2024). Economic evaluation of anti-epileptic medicines for autistic children with epilepsy. Journal of Autism and Developmental Disorders, 54(7), 2733 – 2741. https://doi.org/10.1007/s10803-023-05941-8 picture_as_pdf
  • Viehbeck, Constance (2024). Expedited approvals and adverse drug reactions in women. The Lancet, 403(10441), 2289 - 2290. https://doi.org/10.1016/S0140-6736(23)02353-X picture_as_pdf
  • Zaitceva, V, Tan, I, Mills, M., Kanavos, P. (2024). HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA. Value in Health, 27(12, Supplement), S323 - S323. https://doi.org/10.1016/j.jval.2024.10.1677
  • Zisis, K., Karampli, E., Nomikos, N., Agorastos, I, Naoum, P., Tsiantou, V, Kyriopoulos, I, Pavi, E. (2024). HPR240 A rapid review of key challenges and success factors in implementing managed entry agreements for pharmaceuticals: lessons for Greece. Value in Health, 27(12, Supplement), S320 - S321. https://doi.org/10.1016/j.jval.2024.10.1664
    • 2023
  • Allum, Nick, Reid, Abigail, Bidoglia, Miriam, Gaskell, George, Aubert-Bonn, Noémie, Buljan, Ivan, Fuglsang, Simon, Horbach, Serge, Kavouras, Panagiotis & Marušić, Ana et al (2023). Researchers on research integrity: a survey of European and American researchers. F1000Research, 12, p. 187. https://doi.org/10.12688/f1000research.128733.1 picture_as_pdf
  • Alsaadi, Fawaz E., Yasami, Amirreza, Volos, Christos, Bekiros, Stelios, Jahanshahi, Hadi (2023). A new fuzzy reinforcement learning method for effective chemotherapy. Mathematics, 11(2). https://doi.org/10.3390/math11020477 picture_as_pdf
  • Angelis, Aris, Polyakov, Roman, Wouters, Olivier J., Torreele, Els, McKee, Martin (2023). High drug prices are not justified by industry’s spending on research and development. BMJ, 380(8371). https://doi.org/10.1136/bmj-2022-071710 picture_as_pdf
  • Bosch, B., Sokhela, S., Akpomiemie, G., Chandiwana, N., Venter, W.D.F., Simmons, Bryony, McCann, K., Mirchandani, M., Hill, A. (2023). High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial. Journal of the International AIDS Society, 26(S3), 11 - 11. https://doi.org/10.1002/jia2.26134
  • Camprubí-Ferrer, Daniel, Ramponi, Francesco, Balerdi-Sarasola, Leire, Godoy, Ana, Sicuri, Elisa, Muñoz, José (2023). Rapid diagnostic tests for dengue would reduce hospitalizations, healthcare costs and antibiotic prescriptions in Spain: a cost-effectiveness analysis. Enfermedades Infecciosas y Microbiologia Clinica, https://doi.org/10.1016/j.eimc.2022.12.009 picture_as_pdf
  • Carpena, Marina Xavier, Paula, Cristiane Silvestre, De Mola, Christian Loret, Hessel, Philipp, Avendano, Mauricio, Evans-Lacko, Sara, Matijasevich, Alicia (2023). Combining cash transfers and cognitive behavioral therapy to reduce antisocial behavior in young men: a mediation analysis of a randomized controlled trial in Liberia. PLOS ONE, 18(3). https://doi.org/10.1371/journal.pone.0273891 picture_as_pdf
  • Cirera, Laia, Sacoor, Charfudin, Meremikwu, Martin, Ranaivo, Louise, Manun'ebo, Manu F., Pons-Duran, Clara, Arikpo, Dachi, Ramirez, Maximo, Ramponi, Francesco & Figueroa-Romero, Antia et al (2023). Cost-effectiveness of community-based distribution of intermittent preventive treatment of malaria in pregnancy in Madagascar, Mozambique, Nigeria, and the Democratic Republic of Congo. BMJ Global Health, 8(7). https://doi.org/10.1136/bmjgh-2022-010238 picture_as_pdf
  • Clarke, Jeremy (2023). From here to I.A.P.T? (improving access to psychological therapies), preview for a new deal for dynamic psychotherapies: the psychoanalyst as street-level bureaucrat. International Journal of Applied Psychoanalytic Studies, 20(2), 316-324. https://doi.org/10.1002/aps.1814 picture_as_pdf
  • Clarke, Jeremy (2023). A new deal for dynamic psychotherapies: the psychoanalyst as street‐level bureaucrat. International Journal of Applied Psychoanalytic Studies, 20(4), 619 - 650. https://doi.org/10.1002/aps.1848 picture_as_pdf
  • Davis, Courtney, Wagner, Anita K., Salcher-Konrad, Maximilian, Scowcroft, Henry, Mintzes, Barbara, Pokorny, Adrian M J, Lew, Jianhui, Naci, Huseyin (2023). Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ, 380, e073711. https://doi.org/10.1136/bmj-2022-073711 picture_as_pdf
  • Feldman, William B., Tu, S. Sean, Alhiary, Rasha, Kesselheim, Aaron S., Wouters, Olivier J. (2023). Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. JAMA, 329(1), 87 - 89. https://doi.org/10.1001/jama.2022.19691 picture_as_pdf
  • Forrest, Robin (19 January 2023) The size of the US pharmaceutical market means that the US Food and Drug Administration has a disproportionately large global influence. USApp – American Politics and Policy Blog. picture_as_pdf
  • Gill, Jennifer L, Miracolo, Aurelio, Politopoulou, Konstantina, Jayawardana, Sahan, Apostolou, Efstratios A., Carter, Alex, Kanavos, Panos (2023). MSR1 Estimating lifetime benefits of optimizing secondary preventive treatment for atherosclerotic cardiovascular disease. Value in Health, 26(12), S393 - S393. https://doi.org/10.1016/j.jval.2023.09.2060
  • Guzman-Castillo, Maria, Korhonen, Kaarina, Murphy, Michael, Martikainen, Pekka (2023). Projections of future burden of pharmacologically treated type 2 diabetes and associated life expectancies by income in Finland: a multi-state modeling study. Frontiers in Public Health, 11, https://doi.org/10.3389/fpubh.2023.1141452 picture_as_pdf
  • Jenei, Kristina, Meyers, Daniel (2023). Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations. BMJ Open, 13(10). https://doi.org/10.1136/bmjopen-2022-066378 picture_as_pdf
  • Mazumdar, Papiya, Zavala, Gerardo, Aslam, Faiza, Muliyala, Krishna Prasad, Chaturvedi, Santosh Kumar, Kandasamy, Arun, Nizami, Asad, Ul Haq, Baha, Kellar, Ian & Jackson, Cath et al (2023). IMPACT smoking cessation support for people with severe mental illness in South Asia (IMPACT 4S): a protocol for a randomised controlled feasibility trial of a combined behavioural and pharmacological support intervention. PLOS ONE, 18(6). https://doi.org/10.1371/journal.pone.0287185 picture_as_pdf
  • Mills, Mackenzie (2023). HTA barriers for conditional approval drugs. PharmacoEconomics, 41(5), 529 - 545. https://doi.org/10.1007/s40273-023-01248-9 picture_as_pdf
  • Mills, Mackenzie, Kanavos, Panos (2023). Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products: evidence from nine OECD countries. PharmacoEconomics - Open, 7(4), 553 - 565. https://doi.org/10.1007/s41669-023-00406-1 picture_as_pdf
  • Naci, Huseyin, Forrest, Robin, Zhai, Mike, Stofesky, Amanda R., Kesselheim, Aaron S. (2023). Characteristics of prior authorization policies for new drugs in Medicare Part D. JAMA Health Forum, 4(2). https://doi.org/10.1001/jamahealthforum.2022.5610 picture_as_pdf
  • Narendrula, Aparna, Lang, Jacob, Mossialos, Elias (2023). Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model. Frontiers in Pharmacology, 14, https://doi.org/10.3389/fphar.2023.1179253 picture_as_pdf
  • Needham, Brian Richard (2023). Snake oil or super drug how have regulators and payers perceived new medicines that target asymptomatic conditions? Health Technology Assessment in Action, 7(3). https://doi.org/10.18502/htaa.v7i3.14208 picture_as_pdf
  • Nikoloski, Zlatko, Aliyev, Elnur, Bain, Robert E.S., Menchini, Leonardo, Hegazi, Sahar, Zalkha, Mai, Mouawad, Shaza, Kapil, Neha, Gillespie, Amaya M. (2023). COVID-19 vaccination personas in Syria: evidence from a cross-sectional survey. Vaccines, 11(6). https://doi.org/10.3390/vaccines11061109 picture_as_pdf
  • Nikoloski, Zlatko, Chimenya, Dennis, Alshehari, Abdullah, Hassan, Hauwa, Bain, Robert, Menchini, Leonardo, Gillespie, Amaya (2023). COVID-19 vaccination personas in Yemen: insights from three rounds of a cross-sectional survey. Vaccines, 11(7). https://doi.org/10.3390/vaccines11071272 picture_as_pdf
  • Politopoulou, Konstantina, Mills, Mackenzie, Kanavos, Panos (2023). HTA255 First-in-class drugs in HTA blunder or bliss? Value in Health, 26(12), S369 - S369. https://doi.org/10.1016/j.jval.2023.09.1938
  • Sullivan, Sean D. (2023). Medicare drug price negotiation in the United States: implications and unanswered questions. Value in Health, 26(3), 394-399. https://doi.org/10.1016/j.jval.2022.11.015
  • Sullivan, Sean D., Hernandez, Inmaculada, Ramsey, Scott D., Neumann, Peter J. (2023). Has the Centers for Medicare & Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations? Value in Health, 26(12), 1686 - 1688. https://doi.org/10.1016/j.jval.2023.10.004
  • Tedeschi, Eduardo, Hoffmann, Mauricio Scopel, Magalhaes, Pedro V. S. (2023). Relative impact of diagnosis and clinical stage on response to electroconvulsive therapy: a retrospective cohort. Brazilian Journal of Psychiatry, 45(4), 334 - 337. https://doi.org/10.47626/1516-4446-2023-3058 picture_as_pdf
  • Vokinger, Kerstin N., Perényi, Gellért, Wouters, Olivier J. (2023). Investments in research and development for supplemental drug indications: implications for drug price negotiations. JAMA Health Forum, 4(9), E232798. https://doi.org/10.1001/jamahealthforum.2023.2798 picture_as_pdf
  • Zhou, Yue, Naci, Huseyin, Chen, Dingyi, Bai, Lin, Shi, Luwen, Guan, Xiaodong, Wagner, Anita Katharina (2023). Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021. BMJ Global Health, 8(9). https://doi.org/10.1136/bmjgh-2023-012899 picture_as_pdf
    • 2022
  • Bartholomew, Theodore, Naci, Huseyin, Robertson, Emma, Schmidt, Harald (2022). Use of adherence monitoring in drug contracts tied to outcomes: put patients first. BMJ (Clinical research ed.), 376, https://doi.org/10.1136/bmj-2020-062188 picture_as_pdf
  • Bingel, Anne, Messroghli, Daniel, Weimar, Andreas, Runte, Kilian, Salcher-Konrad, Maximilian, Kelle, Sebastian, Pieske, Burkert, Berger, Felix, Kuehne, Titus & Goubergrits, Leonid et al (2022). Hemodynamic changes during physiological and pharmacological stress testing in patients with heart failure: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 9, https://doi.org/10.3389/fcvm.2022.718114 picture_as_pdf
  • Blankart, Katharina, Naci, Huseyin, Chandra, Amitabh (2022). Availability of new medicines in the US and Germany from 2004 to 2018. JAMA network open, 5(8). https://doi.org/10.1001/jamanetworkopen.2022.29231 picture_as_pdf
  • Cherla, Avi, Mossialos, Elias, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Naci, Huseyin (2022). Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. Clinical Pharmacology and Therapeutics, 112(4), 846 - 852. https://doi.org/10.1002/cpt.2679 picture_as_pdf
  • Chisholm, Orin, Sharry, Patrick, Phillips, Lawrence (2022). Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities. Frontiers in Medicine, 8, https://doi.org/10.3389/fmed.2021.820335 picture_as_pdf
  • Costa, Suzete, Romão, Mariana, Mendes, Maria, Horta, Maria Rute, Rodrigues, António Teixeira, Carneiro, António Vaz, Martins, Ana Paula, Mallarini, Erika, Naci, Huseyin, Babar, Zaheer Ud Din (2022). Pharmacy interventions on COVID-19 in Europe: mapping current practices and a scoping review. Research in Social and Administrative Pharmacy, 18(8), 3338 - 3349. https://doi.org/10.1016/j.sapharm.2021.12.003 picture_as_pdf
  • Dimitriadis, Konstantinos, Kyriopoulos, Ilias, Tsivgoulis, Georgios, Vemmos, Konstantinos, Kunz, Wolfgang G., Mossialos, Elias (2022). Moving from traditional to more advanced treatments in stroke care is cost-effective: a case study from Greece. Journal of Stroke and Cerebrovascular Diseases, 31(11). https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106764
  • Efthymiadou, Anastasia Olga (2022). The role of “Managed Entry Agreements” in managing the market entry of new, high-cost, cancer medicines. The determinants and the impact of agreements implemented in Australia, England, Scotland and Sweden, as part of Health Technology Assessment processes [Doctoral thesis]. London School of Economics and Political Science. https://doi.org/10.21953/lse.00004565
  • Efthymiadou, Olina (2022). Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries. European Journal of Health Economics, https://doi.org/10.1007/s10198-022-01526-x picture_as_pdf
  • Efthymiadou, Olina, Kanavos, Panos (2022). Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries. BMC Health Services Research, 22(1). https://doi.org/10.1186/s12913-022-08437-w picture_as_pdf
  • Fonseca, Elize M.da, Jarman, Holly, King, Elizabeth J., Greer, Scott L. (2022). Perspectives in the study of the political economy of COVID-19 vaccine regulation. Regulation and Governance, 16(4), 1283-1289. https://doi.org/10.1111/rego.12413 picture_as_pdf
  • Fontrier, Anna-Maria (2022). Market access for medicines treating rare diseases: association between specialised processes for orphan medicines and funding recommendations. Social Science & Medicine, 306, https://doi.org/10.1016/j.socscimed.2022.115119 picture_as_pdf
  • Haas, Julia W., Ongaro, Giulio, Jacobson, Eric, Conboy, Lisa A., Nee, Judy, Iturrino, Johanna, Rangan, Vikram, Lembo, Anthony, Kaptchuk, Ted J., Ballou, Sarah (2022). Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study. BMC Psychology, 10(1). https://doi.org/10.1186/s40359-022-00731-w picture_as_pdf
  • Henderson, Catherine, Knapp, Martin, Fossey, Jane, Frangou, Elena, Ballard, Clive (2022). Cost-effectiveness of an online intervention for caregivers of people living with dementia. Journal of the American Medical Directors Association, 23(9), 1468 - 1473. https://doi.org/10.1016/j.jamda.2022.03.002 picture_as_pdf
  • Henderson, Catherine, Knapp, Martin, Stirling, Susan, Shepstone, Lee, High, Juliet, Ballard, Clive, Bentham, Peter, Burns, Alistair, Farina, Nicolas & Fox, Chris et al (2022). Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial. International Psychogeriatrics, 34(10), 905 - 917. https://doi.org/10.1017/S1041610222000436 picture_as_pdf
  • Keeler, Johanna Louise, Chami, Rayane, Cardi, Valentina, Hodsoll, John, Bonin, Eva, MacDonald, Pamela, Treasure, Janet, Lawrence, Natalia (2022). App-based food-specific inhibitory control training as an adjunct to treatment as usual in binge-type eating disorders: a feasibility trial. Appetite, 168, https://doi.org/10.1016/j.appet.2021.105788 picture_as_pdf
  • Kim, Byung-Jun, Park, A-La, Hwang, Man-Suk, Heo, In, Park, Sun-Young, Cho, Jae-Heung, Kim, Koh-Woon, Lee, Jun-Hwan, Ha, In-Hyuk & Park, Kyoung-Sun et al (2022). Comparative effectiveness and safety of concomitant treatment with Chuna Manual Therapy and usual care for whiplash injuries: a multicenter randomized controlled trial. International Journal of Environmental Research and Public Health, 19(17). https://doi.org/10.3390/ijerph191710678 picture_as_pdf
  • Mao, Wenhui, Jiang, Hongli, Mossialos, Elias, Chen, Wen (2022). Improving access to medicines: lessons from 10 years of drug reforms in China, 2009-2020. BMJ Global Health, 7(11). https://doi.org/10.1136/bmjgh-2022-009916 picture_as_pdf
  • Michaeli, Daniel Tobias, Mills, Mackenzie, Michaeli, Thomas, Miracolo, Aurelio, Kanavos, Panos (2022). Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Investigational New Drugs, 40(4), 798 - 809. https://doi.org/10.1007/s10637-022-01227-5 picture_as_pdf
  • Michaeli, Daniel Tobias, Stoycheva, Sophia, Marcus, Simon Mashudu, Zhang, Wenjia, Michaeli, Julia Caroline, Michaeli, Thomas (2022). Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa. Clinical Drug Investigation, 42(4), 333 - 343. https://doi.org/10.1007/s40261-022-01138-6 picture_as_pdf
  • Nutt, David J., Phillips, Lawrence D., Barnes, Michael, Brander, Brigitta, Curran, H. Valerie, Fayaz, Alan, Finn, David P., Horsted, Tina, Moltke, Julie & Sakal, Chloe et al (2022). A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. Cannabis and Cannabinoid Research, 7(4), 482 - 500. https://doi.org/10.1089/can.2020.0129 picture_as_pdf
  • Pandolfo, Alyssa M., Horne, Robert, Jani, Yogini, Reader, Tom W., Bidad, Natalie, Brealey, David, Enne, Virve I., Livermore, David M., Gant, Vanya, Brett, Stephen J. (2022). Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework. BMJ Quality and Safety, 31(3), 199 - 210. https://doi.org/10.1136/bmjqs-2020-012479 picture_as_pdf
  • Schlag, Anne Katrin, Zafar, Rayyan R., Lynskey, Michael T., Athanasiou-Fragkouli, Alkyoni, Phillips, Lawrence D., Nutt, David J. (2022). The value of real world evidence: the case of medical cannabis. Frontiers in Psychiatry, 13, https://doi.org/10.3389/fpsyt.2022.1027159 picture_as_pdf
  • Shadlen, Kenneth C. (2022). Accelerating pooled licensing of medicines to enhance global production and equitable access. The Lancet, 400(10352), 632-634. https://doi.org/10.1016/S0140-6736(22)01013-3
  • Sokhela, Simiso, Bosch, Bronwyn, Hill, Andrew, Simmons, Bryony, Woods, Joana, Johnstone, Hilary, Akpomiemie, Godspower, Ellis, Leah, Owen, Andrew & Casas, Carmen Perez et al (2022). Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. The Journal of Antimicrobial Chemotherapy, 77(10), 2706 - 2712. https://doi.org/10.1093/jac/dkac266 picture_as_pdf
  • Striley, Catherine W., Hoeflich, Carolin C., Viegas, Andrew T., Berkowitz, Lindsey A., Matthews, Emily G., Akin, Leyla P., Iheanyi-Okeahialam, Chidinma, Mansoor, Urmeen, McCurdy, Christopher R. (2022). Health effects associated with Kratom (Mitragyna speciosa) and polysubstance use: a narrative review. Substance Abuse: Research and Treatment, 16, https://doi.org/10.1177/11782218221095873 picture_as_pdf
  • Talat, Usman, Schmidtke, Kelly Ann, Khanal, Saval, Chan, Amy, Turner, Alice, Horne, Robert, Chadborn, Tim, Gold, Natalie, Sallis, Anna, Vlaev, Ivo (2022). A systematic review of nudge interventions to optimize medication prescribing. Frontiers in Pharmacology, 13, https://doi.org/10.3389/fphar.2022.798916 picture_as_pdf
  • Van Staa, Tjeerd, Li, Yan, Gold, Natalie, Chadborn, Tim, Welfare, William, Palin, Victoria, Ashcroft, Darren M., Bircher, Joanna (2022). Comparing antibiotic prescribing between clinicians in UK primary care: an analysis in a cohort study of eight different measures of antibiotic prescribing. BMJ Quality & Safety, 31(11), 831 - 838. https://doi.org/10.1136/bmjqs-2020-012108 picture_as_pdf
  • Vokinger, Kerstin N., Hwang, Thomas J., Carl, David L., Laube, Yannic, Ludwig, Wolf Dieter, Naci, Huseyin, Kesselheim, Aaron S. (2022). Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. The Lancet Oncology, 23(4), 514 - 520. https://doi.org/10.1016/S1470-2045(22)00073-0
  • Vokinger, Kerstin N., Naci, Huseyin (2022). Negotiating drug prices in the US - lessons from Europe. JAMA Health Forum, 3(12). https://doi.org/10.1001/jamahealthforum.2022.4801 picture_as_pdf
  • Wouters, Olivier J., Berenbrok, Lucas A., He, Meiqi, Li, Yihan, Hernandez, Inmaculada (2022). Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. JAMA network open, 5(9). https://doi.org/10.1001/jamanetworkopen.2022.18623 picture_as_pdf
  • Wouters, Olivier J., Feldman, William B., Tu, S. Sean (2022). Product hopping in the drug industry — lessons from Albuterol. New England Journal of Medicine, 387(13), 1153 - 1156. https://doi.org/10.1056/NEJMp2208613 picture_as_pdf
  • Yan, Vincent K.C., Haendler, Miriam, Lau, Hayden, Li, Xue, Lao, Kim S.J., Tsui, Sik Hon, Yap, Celene Y.L., Knapp, Martin, Chan, Esther W. (2022). Cost-effectiveness of Midazolam versus Haloperidol versus Olanzapine for the management of acute agitation in the Accident and Emergency department. Value in Health, 25(7), 1099 - 1106. https://doi.org/10.1016/j.jval.2021.11.1374 picture_as_pdf
  • Zhang, Yichen, Naci, Huseyin, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen, Guan, Xiaodong (2022). Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA network open, 5(8). https://doi.org/10.1001/jamanetworkopen.2022.25973 picture_as_pdf
    • 2021
  • Banerjee, Sube, High, Juliet, Stirling, Susan, Shepstone, Lee, Swart, Ann Marie, Telling, Tanya, Henderson, Catherine, Ballard, Clive, Bentham, Peter & Burns, Alistair et al (2021). Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. The Lancet, 398(10310), 1487 - 1497. https://doi.org/10.1016/S0140-6736(21)01210-1 picture_as_pdf
  • Cherla, Avi, Naci, Huseyin, Mossialos, Elias (2021). The coverage in England of US-approved cancer drugs reply: in reply. JAMA Internal Medicine, 181(9), 1263 - 1264. https://doi.org/10.1001/jamainternmed.2021.3339
  • Fu, Mengyuan, Naci, Huseyin, Booth, Christopher M., Gyawali, Bishal, Cosgrove, Austin, Toh, Sengwee, Xu, Ziyue, Guan, Xiaodong, Ross-Degnan, Dennis, Wagner, Anita K. (2021). Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 181(12), 1596 - 1604. https://doi.org/10.1001/jamainternmed.2021.5983
  • Jayawardana, Sahan, Forman, Rebecca, Johnston-Webber, Charlotte, Campbell, Allen, Berterame, Stefano, de Joncheere, Cees, Aitken, Murray, Mossialos, Elias (2021). Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. EClinicalMedicine, 42, https://doi.org/10.1016/j.eclinm.2021.101198 picture_as_pdf
  • Naci, Huseyin, Guan, Xiaodong, Woloshin, Steven, Xu, Ziyue, Wagner, Anita K. (2021). Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. JAMA Internal Medicine, 181(11), 1521 - 1522. https://doi.org/10.1001/jamainternmed.2021.3505 picture_as_pdf
  • Pokladnikova, Jitka, Park, A-La, Draessler, Jan, Lukacisinova, Anna, Krcmova, Irena (2021). The use of complementary and alternative medicine by adults with allergies: a Czech national representative survey. BMC Complementary Medicine and Therapies, 21(1). https://doi.org/10.1186/s12906-021-03316-z picture_as_pdf
  • Serra-Sastre, Victoria, Bianchi, Simona, Mestre-Ferrandiz, Jorge, O’Neill, Phill (2021). Does NICE influence the adoption and uptake of generics in the UK? European Journal of Health Economics, 22(2), 229 - 242. https://doi.org/10.1007/s10198-020-01245-1 picture_as_pdf
  • Zafar, Rayyan, Schlag, Anne, Phillips, Lawrence, Nutt, David J. (2021). Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. BMJ Paediatrics Open, 5(1). https://doi.org/10.1136/bmjpo-2021-001234 picture_as_pdf
    • 2020
  • Angelis, Aris, Linch, Mark, Montibeller, Gilberto, Molina Lopez, Maria Teresa, Zawada, Anna, Orzel, Kinga, Arickx, Francis, Espin, Jaime, Kanavos, Panos (2020). Multiple criteria decision analysis for HTA across four EU member states: piloting the Advance Value Framework. Social Science & Medicine, 246, https://doi.org/10.1016/j.socscimed.2019.112595 picture_as_pdf
  • Angelis, Aris, Naci, Huseyin, Hackshaw, Allan (2020). Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics, 38(12), 1297-1308. https://doi.org/10.1007/s40273-020-00956-w picture_as_pdf
  • Angelis, Aris, Thursz, Mark, Ratziu, Vlad, O'Brien, Alistair, Serfaty, Lawrence, Canbay, Ali, Schiefke, Ingolf, Bana e Costa, João C., Lecomte, Pascal, Kanavos, Panos (2020). Early health technology assessment during nonalcoholic steatohepatitis drug development: a two-round, cross-country, multicriteria decision analysis. Medical Decision Making, 40(6), 830 - 845. https://doi.org/10.1177/0272989X20940672 picture_as_pdf
  • Bauer, Annette, Wittenberg, Raphael, Ly, Amanda, Gustavsson, Anders, Bexelius, Christin, Tochel, Claire, Knapp, Martin, Nelson, Mia, Sudlow, Catherine (2020). Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes. International Journal of Technology Assessment in Health Care, 36(4), 297 - 303. https://doi.org/10.1017/S0266462320000574 picture_as_pdf
  • Dean, Megan (24 January 2020) Book review: the politics of weight: feminist dichotomies of power in dieting by Amelia Morris. LSE Review of Books. picture_as_pdf
  • Luyten, Jeroen, McKee, Martin, Wouters, Olivier J. (2020). Wat kost onderzoek en ontwikkeling van een medicijn? Een oproep tot meer transparantie. Nederlands Tijdschrift voor Geneeskunde, 164(34). picture_as_pdf
  • Naci, Huseyin, Kesselheim, Aaron S., Rttingen, John Arne, Salanti, Georgia, Vandvik, Per O., Cipriani, Andrea (2020). Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. The BMJ, 371, https://doi.org/10.1136/bmj.m3869 description
  • Nutt, David, Bazire, Steve, Phillips, Lawrence D., Schlag, Anne Katrin (2020). So near yet so far why won't the UK prescribe medical cannabis? BMJ Open, 10(9). https://doi.org/10.1136/bmjopen-2020-038687 picture_as_pdf
  • Sallis, Anna, Bondaronek, Paulina, Sanders, Jet G., Yu, Ly Mee, Harris, Victoria, Vlaev, Ivo, Sanders, Michael, Tonkin-Crine, Sarah, Chadborn, Tim (2020). Prescriber commitment posters to increase prudent antibiotic prescribing in English general practice: a cluster randomized controlled trial. Antibiotics, 9(8). https://doi.org/10.3390/antibiotics9080490 picture_as_pdf
  • Stoner, Charlotte R, Knapp, Martin, Luyten, Jeroen, Kung, Claryn, Richards, Marcus, Rossor, Martin (2020). The cognitive footprint of medication: a review of cognitive assessments in clinical trials. Journal of Clinical Pharmacy and Therapeutics, 45(4), 874 - 880. https://doi.org/10.1111/jcpt.13151 picture_as_pdf
  • Vreman, Rick A., Naci, Huseyin, Goettsch, Wim G., Mantel-Teeuwisse, Aukje K., Schneeweiss, Sebastian G., Leufkens, Hubert G.M., Kesselheim, Aaron S. (2020). Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108(2), 350-357. https://doi.org/10.1002/cpt.1835 picture_as_pdf
  • Wouters, Olivier J., McKee, Martin, Luyten, Jeroen (2020). Research and development costs of new drugs: in reply. JAMA, 324(5), p. 518. https://doi.org/10.1001/jama.2020.8651
    • 2019
  • CARDIOPROOF group (2019). Publisher correction: model-based therapy planning allows prediction of haemodynamic outcome after aortic valve replacement. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-018-36022-x
  • Clare, Linda, Kudlicka, Aleksandra, Oyebode, Jan R., Jones, Roy W., Bayer, Antony, Leroi, Iracema, Kopelman, Michael, James, Ian A., Culverwell, Alison & Pool, Jackie et al (2019). Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT. Health Technology Assessment, 23(10), 1-242. https://doi.org/10.3310/hta23100
  • Jones, Daniel A., Whittaker, Peter, Rathod, Krishnaraj S., Richards, Amy J., Andiapen, Mervyn, Antoniou, Sotiris, Mathur, Anthony, Ahluwalia, Amrita (2019). Sodium nitrite–mediated cardioprotection in primary percutaneous coronary intervention for ST-Segment Elevation Myocardial Infarction: a cost-effectiveness analysis. Journal of Cardiovascular Pharmacology and Therapeutics, 24(2), 113-119. https://doi.org/10.1177/1074248418784940
  • Keeyaa, Chaurey (2019). Pirates and property: the moralities of branded and generic medicines [Masters thesis]. London School of Economics and Political Science. picture_as_pdf
  • Lomas, James, Asaria, Miqdad, Bojke, Laura, Gale, Chris P., Richardson, Gerry, Walker, Simon (2019). Correction to: which costs matter? Costs included in economic evaluation and their impact on decision uncertainty for stable coronary artery disease. PHARMACOECONOMICS-OPEN, 3(2), p. 277. https://doi.org/10.1007/s41669-019-0129-0 picture_as_pdf
  • Massard da Fonseca, Elize, Shadlen, Kenneth C., Inácio Bastos, Francisco (2019). Brazil’s fight against Hepatitis C: universalism, local production, and patents. New England Journal of Medicine, 380(7), 605-607. https://doi.org/10.1056/NEJMp1812959 picture_as_pdf
  • Naci, Huseyin, Davis, Courtney, Savović, Jelena, Higgins, Julian P. T., Sterne, Jonathan, Gyawali, Bishal, Romo Sandoval, Xochitl Citlalli, Handley, Nicola, Booth, Christopher M (2019). Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross-sectional analysis. BMJ, 366(8214). https://doi.org/10.1136/bmj.l5221 picture_as_pdf
  • Naci, Huseyin, Salcher-Konrad, Maximilian, Mcguire, Alistair, Berger, Felix, Kuehne, Titus, Goubergrits, Leonid, Muthurangu, Vivek, Wilson, Ben, Kelm, Marcus (2019). Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. npj Digital Medicine, 2(1). https://doi.org/10.1038/s41746-019-0085-1 picture_as_pdf
  • Neez, Emilie Marie Celine Anne, Hwang, Thomas, Sahoo, Samali Anova, Naci, Huseyin (2019). European Medicines Agency’s Priority Medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. Clinical Pharmacology and Therapeutics, 107(3), 541-552. https://doi.org/10.1002/cpt.1669 picture_as_pdf
  • Randell, Elizabeth, McNamara, Rachel, Delport, Sue, Busse, Monica, Hastings, Richard P., Gillespie, David, Williams-Thomas, Rhys, Brookes-Howell, Lucy, Romeo, Renee & Boadu, Janet et al (2019). Sensory integration therapy versus usual care for sensory processing difficulties in autism spectrum disorder in children: study protocol for a pragmatic randomised controlled trial. Trials, 20(1). https://doi.org/10.1186/s13063-019-3205-y
  • Tervonen, Tommi, Angelis, Aris, Hockley, Kimberley, Pignatti, Francesco, Phillips, Lawrence D. (2019). Quantifying preference in drug benefit-risk decisions. Clinical Pharmacology and Therapeutics, 106(5), 955-959. https://doi.org/10.1002/cpt.1447 picture_as_pdf
  • Vermersch, Patrick, Martinelli, Vittorio, Pfleger, Claudia, Rieckmann, Peter, Alonso-Magdalena, Lucia, Galazka, Andrew, Dangond, Fernando, Phillips, Lawrence D. (2019). Benefit-risk assessment of cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis. Clinical Therapeutics, 41(2), 249-260. https://doi.org/10.1016/j.clinthera.2018.12.015 picture_as_pdf
  • Visintin, Erica, Tinelli, Michela, Kanavos, Panos (2019). Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. Health Policy, 123(2), 118-129. https://doi.org/10.1016/j.healthpol.2018.08.019
    • 2018
  • ATLAS Triallists Group (2018). Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Health Technology Assessment, 22(67), vii-60. https://doi.org/10.3310/hta22670 picture_as_pdf
  • Ghabri, Salah, Stevenson, Matt, Möller, Jörgen, Caro, J. Jaime (2018). Trusting the results of model-based economic analyses: is there a pragmatic validation solution? PharmacoEconomics, https://doi.org/10.1007/s40273-018-0711-9 picture_as_pdf
  • Gill, Jennifer, Kanavos, Panos, d'Angela, Daniela, Berger, Karin, Dank, Magdolna, Duncombe, Robert, Fink-Wagner, Antje, Hutton, John, Kossler, Ingrid & Podrazilova, Katerina et al (2018). RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap. London School of Economics and Political Science. https://doi.org/10.21953/lse.anw9nzz3qqkp
  • Naci, Huseyin, Salcher-Konrad, Maximilian, Dias, Sofia, Blum, Manuel R., Sahoo, Samali Anova, Nunan, David, Ioannidis, John P. A. (2018). How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 RCTs assessing exercise and medication effects on systolic blood pressure. British Journal of Sports Medicine, https://doi.org/10.1136/bjsports-2018-099921 picture_as_pdf
  • Rogeberg, Ole, Bergsvik, Daniel, Phillips, Lawrence D., Amsterdam, Jan van, Eastwood, Niamh, Henderson, Graeme, Lynskey, Michael, Measham, Fiona, Ponton, Rhys & Rolles, Steve et al (2018). A new approach to formulating and appraising drug policy: a multi-criterion decision analysis applied to alcohol and cannabis regulation. International Journal of Drug Policy, https://doi.org/10.1016/j.drugpo.2018.01.019
  • Wallach, Joshua D., Ross, Joseph S., Naci, Huseyin (2018). The US Food and Drug Administration’s expedited approval programs: addressing premarket flexibility with enhanced postmarket evidence generation. Clinical Trials, 15(3), 243-246. https://doi.org/10.1177/1740774518770657
    • 2017
  • Bojke, Laura, Manca, Andrea, Asaria, Miqdad, Mahon, Ronan, Ren, Shijie, Palmer, Stephen (2017). How to appropriately extrapolate costs and utilities in cost-effectiveness analysis. PharmacoEconomics, 35(8), 767-776. https://doi.org/10.1007/s40273-017-0512-6
  • Cornford, Tony (2017). The digital future beyond the pill.
  • Dhami, S., Kakourou, A., Asamoah, F., Agache, I., Lau, S., Jutel, M., Muraro, A., Roberts, G., Akdis, C. A. & Bonini, M. et al (2017). Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 72(12), 1825-1848. https://doi.org/10.1111/all.13208
  • Dhami, S., Zaman, H., Varga, E. M., Sturm, G. J., Muraro, A., Akdis, C. A., Antolín-Amérigo, D., Bilò, M. B., Bokanovic, D. & Calderon, M. A. et al (2017). Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 72(3), 342-365. https://doi.org/10.1111/all.13077
  • Dickson, Jane (2017). Vocal biomarkers: diagnostics through human voice.
  • Dickson, Jane (2017). Warfarin history timeline.
  • Hibberd, Ralph (2017). Brexit and the falsified medicines directive.
  • Kapczynski, Amy, Sampat, Bhaven N., Shadlen, Kenneth C. (2017). Trade agreements, patents, and drug prices: continuing the debate. (Research Paper 572). John M. Olin Center for Studies in Law, Economics, and Public Policy, Yale Law School.
  • Manfrin, Andrea, Tinelli, Michela, Thomas, Trudy, Krska, Janet (2017). A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients. BMC Health Services Research, 17, https://doi.org/10.1186/s12913-017-2245-9
  • Salas-Vega, Sebastian, Iliopoulos, Othon, Mossialos, Elias (2017). Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncology, 3(3), 382-390. https://doi.org/10.1001/jamaoncol.2016.4166
  • Williams, Thomas Christie (2017). Long read review: drug dealer, MD: how doctors were duped, patients got hooked and why it’s so hard to stop by Anna Lembke.
  • Wouters, Olivier J., Kanavos, Panos, McKee, Martin (2017). Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. The Milbank Quarterly, 95(3), 554 - 601. https://doi.org/10.1111/1468-0009.12279
    • 2016
  • AFFECT Investigators (2016). A randomised controlled trial of calcium channel blockade (CCB) with amlodipine for the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. Trials, 17(1). https://doi.org/10.1186/s13063-016-1449-3
  • Dickson, Jane (2016). $1 million for a drug used once.
  • Feliu-Soler, Albert, Borràs, Xavier, Peñarrubia-María, María T., Rozadilla-Sacanell, Antoni, D’Amico, Francesco, Moss-Morris, Rona, Howard, Matthew A., Fayed, Nicolás, Soriano-Mas, Carles & Puebla-Guedea, Marta et al (2016). Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). BMC Complementary and Alternative Medicine, 16(1). https://doi.org/10.1186/s12906-016-1068-2
  • Gyawali, Bishal, Ferrario, Alessandra, van Teijlingen, Edwin, Kallestrup, Per (2016). Challenges in diabetes mellitus type 2 management in Nepal: a literature review. Global Health Action, 9(1). https://doi.org/10.3402/gha.v9.31704
  • Hamilton, Zoe, Munger, Anne (2016). Rhetoric vs reality: contraception in India and the DMPA debate.
  • Hibberd, Ralph (2016). Accelerating access to new drugs in Japan.
  • Hibberd, Ralph (2016). Combating falsified medicines in Africa through digital artefacts.
  • Hibberd, Ralph (2016). Hub and spoke dispensing: privacy and sociotechnical rigidity.
  • Hibberd, Ralph (2016). Hub and spoke dispensing: safety and sociotechnical pliability.
  • Levin, David, Shiner, Michael (2016). New deviancy theory and the healthcare system's role in creating, labeling, and facilitating unauthorized prescription drug “abuse”. Pain Practice, 16(7), 791-793. https://doi.org/10.1111/papr.12458
  • Lichtner, Valentina (2016). ‘the little liar’ – patient information about medicines.
  • Morais de Oliveira, Iago (2016). Using international human rights law to guarantee the right to health: a Brazilian experience.
  • Owen, Geoffrey (7 November 2016) Biotechnology: why is Europe lagging behind the U.S.? LSE Business Review. picture_as_pdf
    • 2015
  • Costa-i-Font, Joan (2015). Parallel trade in medicinal drugs is putting the welfare of EU patients at risk.
  • Dickson, Jane (2015). Enduring and emerging challenges of informed consent.
  • Dickson, Jane (2015). Personalized medicine: a podcast.
  • Dickson, Jane (2015). Stratified medicine in 2015 – Leeds Christmas lecture.
  • Dickson, Jane (2015). A decision support tool for warfarin prescribing.
  • Knapp, Martin, McDaid, David, Park, A-La (2015). Recovery and economics. Die Psychiatrie, 12(3), 162-166.
  • Shadlen, Kenneth C., Sampat, Bhaven N. (9 November 2015) Drug patenting in India: looking back and looking forward. South Asia @ LSE. picture_as_pdf
  • Tzouma, Victoria, Grepstad, Mari, Grimaccia, Federico, Kanavos, Panos (2015). Clinical, ethical, and socioeconomic considerations for prescription drug use during pregnancy in women suffering from chronic diseases. Therapeutic Innovation and Regulatory Science, 49(6), 947-956. https://doi.org/10.1177/2168479015589820
  • Wouters, Olivier J., O'Donoghue, Donal J., Ritchie, James, Kanavos, Panos, Narva, Andrew S. (2015). Early chronic kidney disease: diagnosis, management and models of care. Nature Reviews Nephrology, 11(8), 491-502. https://doi.org/10.1038/nrneph.2015.85
    • 2014
  • Brown, Sally (2014). Book review: The bitterest pills: the troubling story of antipsychotic drugs by Joanna Moncrieff.
  • Coulter, Steve (2014). The war over drugs: what’s at stake?
  • Kravdal, Øystein, Grundy, Emily (2014). Underuse of medication for circulatory disorders among unmarried women and men in Norway? BMC Pharmacology and Toxicology, 15(1), p. 65. https://doi.org/10.1186/2050-6511-15-65
  • Kwong, Danica, Ferrario, Alessandra, Adamski, Jajub, Inotai, Andras, Kalo, Zoltan (2014). Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland. Eurohealth, 20(2), 25-28.
  • Naci, Huseyin, van Valkenhoef, G., Higgins, J. P. T., Fleurence, R., Ades, A. E. (2014). Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. Circulation: Cardiovascular Quality and Outcomes, 7(5), 787-792. https://doi.org/10.1161/CIRCOUTCOMES.114.000825
  • O'Neill, Rachel (2014). As if gender mattered: reconsidering the implications of ‘intoxicating stories’. International Journal of Drug Policy, 25(3), 356-357. https://doi.org/10.1016/j.drugpo.2014.04.005
  • Vandoros, Sotiris (2014). Therapeutic substitution post-patent expiry: the cases of ace inhibitors and proton pump inhibitors. Health Economics, 23(5), 621-630. https://doi.org/10.1002/hec.2935
    • 2013
  • Brogan, David, Mossialos, Elias (2013). Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Globalization and Health, 9(58). https://doi.org/10.1186/1744-8603-9-58
  • Malmström, Rickard E., Godman, Brian B., Diogene, Eduard, Baumgärtel, Christoph, Bennie, Marion, Bishop, Iain, Brzezinska, Anna, Bucsics, Anna, Campbell, Stephen & Ferrario, Alessandra et al (2013). Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 4(39). https://doi.org/10.3389/fphar.2013.00039
  • Ragan, C. Ian, Bard, Imre, Singh, Ilina (2013). What should we do about student use of cognitive enhancers?: an analysis of current evidence. Neuropharmacology, 64, 588-595. https://doi.org/10.1016/j.neuropharm.2012.06.016
  • Shadlen, Kenneth C. (2013). Learning from India? A new approach to secondary pharmaceutical patents. picture_as_pdf
  • Vandoros, Sotiris, Kanavos, Panos (2013). The generics paradox revisited: empirical evidence from regulated markets. Applied Economics, 45(22), 3230-3239. https://doi.org/10.1080/00036846.2012.703313
  • Vandoros, Sotiris, Stargardt, Tom (2013). Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy, 109(1), 1-6. https://doi.org/10.1016/j.healthpol.2012.08.016
    • 2012
  • Helfer, Ana Paula, Camargo, Aline Lins, Tavares, Noemia Urruth Leão, Kanavos, Panos, Bertoldi, Andréa Dâmaso (2012). Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público. Revista Panamericana de Salud Pública/Pan American Journal of Public Health, 31(3), 225-232.
  • Juul, Sissel, Nielsen, Christine J. F., Labouriau, Rodrigo, Roy, Amit, Tesauro, Cinzia, Jensen, Pia W., Harmsen, Charlotte, Kristoffersen, Emil L., Chiu, Ya-Ling & Frøhlich, Rikke et al (2012). Droplet microfluidics platform for highly sensitive and quantitative detection of malaria-causing plasmodium parasites based on enzyme activity measurement. Acs Nano, 6(12), 10676-10683. https://doi.org/10.1021/nn3038594
  • McGuire, Alistair (2012). The European value-pricing game. Expert Review of Pharmacoeconomics and Outcomes Research, 12(1), 5-6. https://doi.org/10.1586/erp.11.85
  • Park, A-La, McDaid, David (2012-05-15 - 2012-05-18) Economic modelling of mindfulness meditation for people with mental health problems [Paper]. International Research Congress on Integrative Medicine and Health, Portland, United States, USA.
  • Shadlen, Kenneth C., Sampat, Bhaven N., Amin, Tahir M. (2012). Balancing innovation and access: India’s pharmaceutical patent laws. picture_as_pdf
  • Towse, A, Drummond, Michael, Sorenson, Corinna (2012). Measuring value: pharmacoeconomics theory and practice. In Danzon, Patricia M., Nicholson, Sean (Eds.), Oxford Handbook on the Economics of the Biopharmaceutical Industry (pp. 394-437). Oxford University Press.
  • Varol, Nebibe, Costa-Font, Joan, McGuire, Alistair (2012). Does adoption of pharmaceutical innovation respond to changes in the regulatory environment? Applied Economic Perspectives and Policy, 34(3), 531-553. https://doi.org/10.1093/aepp/pps027
    • 2011
  • Izugbara, Chimaraoke O., Wekesa, Eliud (2011). Beliefs and practices about antiretroviral medication: a study of poor urban Kenyans living with HIV/AIDS. Sociology of Health and Illness, 33(6), 869-883. https://doi.org/10.1111/j.1467-9566.2010.01328.x
  • Kanavos, Panos, Vandoros, Sotiris (2011). Drugs US: are prices too high?: measuring international pharmaceutical price differences. Significance, 8(1), 15-18. https://doi.org/10.1111/j.1740-9713.2011.00471.x
  • King, Derek, Knapp, Martin, Thomas, P., Razzouk, D., Loze, J.-Y., Kan, H.J., van Baardewijk, M. (2011). Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. Current Medical Research and Opinion, 27(2), 365-374. https://doi.org/10.1185/03007995.2010.542745
  • Naci, Huseyin (2011). The increasing need to harmonize evidence demands of regulators, payers, and health technology assessment bodies in Europe – opportunities and challenges. ISPOR Connections, 17(4), 4-6.
  • Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849
  • Tinelli, Michela, Blenkinsopp, Alison, Bond, Christine (2011). Development, validation and application of a patient satisfaction scale for a community pharmacy medicines-management service. International Journal of Pharmacy Practice, 19(3), 144-155. https://doi.org/10.1111/j.2042-7174.2011.00110.x
  • Towse, Adrian, Drummond, Michael, Sorenson, Corinna (2011). Measuring value: pharmacoeconomics in theory and practice. (Occasional paper 11/03). Office of Health Economics (London, England).
    • 2010
  • Byford, Sarah, Mosweu, Iris (2010). Valuing knowledge of the cost and cost-effectiveness of medicines: commentary on... awareness of the cost of psychotropic medication among doctors. Psychiatrist, 34(9), 369 - 370. https://doi.org/10.1192/pb.bp.110.030155
    • 2009
  • Hong, Jihyung, Dilla, Tatiana, Arellano, Jorge (2009). A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry, 9(1), p. 15. https://doi.org/10.1186/1471-244X-9-15
  • Jones, Rob, Sheehan, Bart, Phillips, Patrick, Knapp, Martin (2009). DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease: a multicentre RCT. Trials, 10(57). https://doi.org/10.1186/1745-6215-10-57
  • Knapp, Martin, Locklear, Julie, Jarbrink, Krister (2009). Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Current Medical Research and Opinion, 25(7), 1593-1603. https://doi.org/10.1185/03007990903010623
  • Sado, Mitsuhiro, Knapp, Martin, Yamauchi, Keita, Fujisawa, Daisuke, So, Mirai, Nakagawa, Atsuo, Kikuchi, Toshiaki, Ono, Yutaka (2009). Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Australian and New Zealand Journal of Psychiatry, 43(6), 539-547. https://doi.org/10.1080/00048670902873664
    • 2008
  • SOHO Study Group (2008). Cost-utility analysis of treatment with Olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the Pan-European SOHO study. PharmacoEconomics, 26(4), 341-358.
  • Kanavos, Panos, Costa-i-Font, Joan, Seeley, Elizabeth (2008). Competition in off-patent drug markets: issues, regulation and evidence. Economic Policy, 23(55), 499-544. https://doi.org/10.1111/j.1468-0327.2008.00207.x
  • Singh, Ilina (2008). Beyond polemics: science and ethics of ADHD. Nature Reviews Neuroscience, 9(12), 957-964. https://doi.org/10.1038/nrn2514
    • 2006
  • Costa-Font, Joan, McDaid, David (2006). Pharmaceutical policy reform in Spain. Eurohealth, 12(4), 14-17.
    • 2005
  • Buskens, Erik, Heeg, Bart M, Knapp, Martin, van Aalast, Gerda, Dries, Pieter J T, de Haan, Lieuwe, van Hout, Ben A (2005). Modelling the treated course of schizophrenia: development of a discrete event simulation model. PharmacoEconomics, 23(s1), 17-33.
  • Fernández, José-Luis, Montgomery, Stuart, Francois, Clément (2005). Evaluation of the cost effectiveness of Escitalopram versus Venlafaxine XR in major depressive disorder. PharmacoEconomics, 23(2), 155-167.
  • Kanavos, Panos, Gemmill, Marin (2005). Pharmaceutical pricing and reimbursement in Europe. Scrip (Firm).
  • McCrone, Paul R., Weeramanthri, Tara, Knapp, Martin R.J., Rushton, Alan, Trowell, Judith, Miles, Gillian, Kolvin, Israel (2005). Cost-effectiveness of individual versus group psychotherapy for sexually abused girls. Child and Adolescent Mental Health, 10(1), 26-31. https://doi.org/10.1111/j.1475-3588.2005.00113.x
  • Surguladze, Simon, Patel, Anita, Kerwin, Robert W, Knapp, Martin, Travis, Michael J (2005). Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29(4), 517-522. https://doi.org/10.1016/j.pnpbp.2005.01.002
    • 2004
  • Campbell, Catherine, Foulis, C. (2004). Creating contexts for effective home-based care of people living with HIV/AIDS. Curationis, 27(3), 5-14.
  • Knapp, Martin, King, Derek, Pugner, Klaus, Lapuerta, Pablo (2004). Non-adherence to antipsychotic medication regimens: associations with resource use and costs. British Journal of Psychiatry, 184(6), 509-516. https://doi.org/10.1192/bjp.184.6.509
    • 2003
  • Duggan, Andy, Warner, Juliet, Knapp, Martin, Kerwin, Robert (2003). Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. British Journal of Psychiatry, 182(6), 505-508. https://doi.org/10.1192/02-538
  • McCrone, Paul R., Chisholm, Daniel, Knapp, Martin, Hughes, Richard, Comi, Giancarlo, Dalakas, Marinos C., Illa, Isabel, Kilindireas, Costas, Nobile-Orazio, Eduardo & Swan, Anthony Victor et al (2003). Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 10(6), 687-694. https://doi.org/10.1046/j.1351-5101.2003.00701.x
    • 2001
  • Tinelli, Michela (2001). Menopausa e terapia ormonale sostitutiva: qualità di vita e farmacoeconomia. Farmacoeconomia News, 3, 15-20.
  • Tinelli, Michela (2001). Progetto pilota per la rilevazione delle prescrizioni farmaceutiche in Farmacia. Cronache Farmaceutiche, 4, 200-204.
    • 2000
  • Almond, Stephen, O'Donnell, Owen (2000). Cost analysis of the treatment of schizophrenia in the UK: a a simulation model comparing olanzapine, risperidone and haloperidol. PharmacoEconomics, 17(4), 383-389.
  • McGuire, Alistair, Burke, T., Goldstein, J., Maniadakis, N., Pettitt, D. (2000). Overview of the Arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology, 39(s2), 33-42. https://doi.org/10.1093/rheumatology/39.suppl_2.33
    • 1999
  • Kanavos, Panos (1999). Financing pharmaceuticals in transition. Croatian Medical Journal, 40(June), 244-259.
    • 1997
  • Le Grand, Julian (1997). Afterword. In Oakley, Ann, Ashton, John (Eds.), The Gift Relationship: From Human Blood to Social Policy . London School of Economics and Political Science.